BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:2024 has revitalized the bacteriophage field\, with over $9 Mi
 llion invested into BiomX and Locus Bioscience\; $24 Million dedicated by
  BARDA to progress bacteriophage therapies to Phase II trials\; and the r
 elease of further regulatory guidelines by agencies.\n\nThe advancement t
 o the clinic has resulted in a wealth of data available to investigate th
 e function\, genetic modification\, and safety of bacteriophages. However
 \, the lack of clarity on the pathway to the market with a sustainable an
 d strategic commercial strategy means that biopharma companies need to re
 think their business model to ensure they are sustainable.\n\nAt the 7th 
 Bacteriophage Therapy Summit\, we'll be diving into the regulatory and in
 vestment landscape for drug developers\, clinical updates showing efficac
 y\, utilizing machine learning\, and developing personalized and off-the-
 shelf therapies to fight AMR in infectious diseases.\n\nDate and Time: Tu
 esday\, 11 March 2025 at 08:00 to Thursday\, 13 March 2025 at 15:45\n
DTEND:20250313T154500
DTSTAMP:20260514T150044Z
DTSTART:20250311T080000
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, Massach
 usetts\, 02116\,
SEQUENCE:0
SUMMARY:2024 has revitalized the bacteriophage field\, with over $9 Millio
 n invested into BiomX and Locus Bioscience\; $24 Million dedicated by BAR
 DA to prog...
UID:e7737ffd-1b58-49de-835b-d115710488d2
END:VEVENT
END:VCALENDAR